Shree Ganesh Remedies Limited (NSE:SGRL)
India · Delayed Price · Currency is INR | Market Cap | 7.80B +24.2% |
| Revenue (ttm) | 919.58M -13.6% |
| Net Income | 121.09M -40.7% |
| EPS | 9.43 -40.7% |
| Shares Out | n/a |
| PE Ratio | 64.57 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,214 |
| Open | 605.05 |
| Previous Close | 629.15 |
| Day's Range | 605.05 - 628.90 |
| 52-Week Range | 490.00 - 749.85 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Jan 29, 2027 |
About Shree Ganesh Remedies
Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India and internationally. The company offers anti-arrhythmic, anti-cancer, anti-depressant, anti-diabetic, anti-diarrheal, antifungal, antihistamine, anti-inflammatory, anti-parasitic, anti-psychotic, anticholinergic, birth-control, cardiovascular, gastrointestinal, neurological disorder, ophthalmic, opioid, and veterinary API intermediates. It also provides fine and specialty c... [Read more]
Financial Performance
In fiscal year 2026, Shree Ganesh Remedies's revenue was 1.09 billion, an increase of 0.63% compared to the previous year's 1.09 billion. Earnings were 177.60 million, a decrease of -23.01%.
Financial StatementsNews
Shree Ganesh Remedies shares tumble over 8% after Q4 net profit drops 48% YoY
Shares of Shree Ganesh Remedies Ltd declined sharply by 8.17% on Tuesday, trading at ₹716 on the BSE, down from the previous close of ₹779.70. The steep fall comes in response to weak Q4 FY25 earnings...
Shree Ganesh Remedies commissions 2.5 MW solar power project, expects Rs 2 crore annual savings
Shree Ganesh Remedies Limited has announced the successful commissioning of a 2.5 MW solar power project, equipped with auto-tracker modules, on March 25, 2025. This project is expected to yield annua...